Reason for request
Inclusion on the lists of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary drug is substantial. |
Clinical Added Value
| no clinical added value |
The Transparency Committee considers that 3rd generation VARNOLINE CONTINU does not provide an improvement in actual benefit (IAB V) compared to 2nd generation oral contraceptives. |
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
JWaDsQWKfEEjEQTF
